Neurometrix (NASDAQ: NURO) and Palomar Medical Technologies (NASDAQ:PMTI) are both small-cap medical equipment, supplies & distribution – nec companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.
Institutional & Insider Ownership
12.6% of Neurometrix shares are held by institutional investors. 4.4% of Neurometrix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Neurometrix and Palomar Medical Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Palomar Medical Technologies||N/A||N/A||N/A|
This is a summary of current ratings for Neurometrix and Palomar Medical Technologies, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Palomar Medical Technologies||0||0||0||0||N/A|
Neurometrix presently has a consensus target price of $3.00, suggesting a potential upside of 123.88%. Given Neurometrix’s higher possible upside, equities analysts clearly believe Neurometrix is more favorable than Palomar Medical Technologies.
Volatility & Risk
Neurometrix has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, Palomar Medical Technologies has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.
Valuation & Earnings
This table compares Neurometrix and Palomar Medical Technologies’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Neurometrix||$12.03 million||0.26||-$14.91 million||($17.01)||-0.08|
|Palomar Medical Technologies||N/A||N/A||N/A||($0.27)||-49.67|
Palomar Medical Technologies has lower revenue, but higher earnings than Neurometrix. Palomar Medical Technologies is trading at a lower price-to-earnings ratio than Neurometrix, indicating that it is currently the more affordable of the two stocks.
Neurometrix beats Palomar Medical Technologies on 6 of the 11 factors compared between the two stocks.
Neurometrix Company Profile
NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.
Palomar Medical Technologies Company Profile
Palomar Medical Technologies, Inc. (Palomar) is a researcher and developer of aesthetic light-based systems for hair removal and other cosmetic procedures, including both lasers and high powered lamps. The Company offers a range of products based on technologies that include, but are not limited to: hair removal; body sculpting, including laser-assisted liposuction; removal of vascular lesions, such as rosacea, spider veins, port wine stains and hemangiomas; wrinkle reduction; removal of leg veins; removal of benign pigmented lesions, such as age and sun spots, freckles and melasma; tattoo removal; acne treatment; skin resurfacing, pseudofolliculitis barbae (PFB) treatment; treatment of red pigmentation in hypertrophic and keloid scars; treatment of verrucae, skin tags and seborrheic keratosis; skin tightening through soft tissue coagulation; scars, and other skin treatments. In June 2013, Cynosure Inc announced the completion of its acquisition of Palomar Medical Technologies Inc.
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.